BIOLASE Past Earnings Performance

Past criteria checks 0/6

BIOLASE's earnings have been declining at an average annual rate of -7.3%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 11.4% per year.

Key information

-7.3%

Earnings growth rate

71.6%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate11.4%
Return on equityn/a
Net Margin-34.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Biolase partners with dental speciality programs across U.S.

Aug 31

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

Jul 21

BIOLASE amends senior secured term loan with SWK Funding

Jul 01

BIOLASE: Bad News Across The Board - Sell

Mar 21

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

Feb 24
Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

Jan 11

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nov 24

Revenue & Expenses Breakdown

How BIOLASE makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:BIOL.Q Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2446-16245
30 Jun 2446-27265
31 Mar 2449-38276
31 Dec 2349-38286
30 Sep 2350-42326
30 Jun 2351-38347
31 Mar 2349-30347
31 Dec 2248-29347
30 Sep 2247-24337
30 Jun 2244-19306
31 Mar 2241-14286
31 Dec 2139-17276
30 Sep 2135-18256
30 Jun 2132-32245
31 Mar 2126-36225
31 Dec 2023-34214
30 Sep 2024-32214
30 Jun 2027-20234
31 Mar 2032-19254
31 Dec 1938-18255
30 Sep 1941-21275
30 Jun 1943-20275
31 Mar 1946-21295
31 Dec 1846-22305
30 Sep 1846-18285
30 Jun 1846-18276
31 Mar 1846-22276
31 Dec 1747-21266
30 Sep 1748-21277
30 Jun 1750-22287
31 Mar 1752-17287
31 Dec 1652-18278
30 Sep 1652-16267
30 Jun 1650-16267
31 Mar 1648-19287
31 Dec 1548-20297
30 Sep 1547-22267
30 Jun 1548-20276
31 Mar 1547-19275
31 Dec 1447-19315
30 Sep 1449-17314
30 Jun 1449-18304
31 Mar 1453-14284
31 Dec 1356-11284

Quality Earnings: BIOL.Q is currently unprofitable.

Growing Profit Margin: BIOL.Q is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIOL.Q is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare BIOL.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOL.Q is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: BIOL.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:09
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BIOLASE, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Bruce JacksonBenchmark Company
Kyle BauserColliers Securities